Medical Weight Loss Upper Marlboro, MD

Clinical studies show that patients using semaglutide typically lose an average of 15% of their initial body weight, while those using tirzepatide may achieve up to 20% weight loss. Individual results vary based on factors such as starting weight, adherence to treatment, and overall health. Dr. Nawrocki will discuss realistic expectations during your consultation based on your specific situation.

The most common side effects are gastrointestinal and include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These effects are typically mild to moderate and often improve as your body adjusts to the medication. Dr. Nawrocki monitors all patients closely and can adjust dosages or provide supportive care to minimize side effects.

Most patients begin seeing noticeable weight loss within the first 4-8 weeks of treatment. Significant results typically occur over 3-6 months of consistent treatment. The duration of your program depends on your individual weight loss goals and how well you respond to the medication. Dr. Nawrocki works with each patient to determine the optimal treatment length.

Ideal candidates typically have a BMI of 27 or higher with weight-related health conditions, or a BMI of 30 or higher. Patients should be committed to making lifestyle changes alongside medication treatment. Dr. Nawrocki evaluates each patient’s medical history and current health status to determine eligibility during the initial consultation.

These medications work by mimicking natural hormones that regulate appetite and blood sugar. They slow gastric emptying, increase feelings of fullness, and reduce food cravings. Tirzepatide has additional benefits by targeting both GLP-1 and GIP receptors, potentially making it more effective than semaglutide for some patients.

Semaglutide targets GLP-1 receptors and typically produces 15% weight loss, while tirzepatide targets both GLP-1 and GIP receptors and may achieve up to 20% weight loss. Tirzepatide’s dual-action mechanism may result in more significant weight loss and better metabolic improvements. Dr. Nawrocki will recommend the most appropriate medication based on your individual needs.

Both semaglutide and tirzepatide are FDA-approved medications with extensive clinical testing demonstrating their safety and effectiveness. When administered under proper medical supervision, these treatments are considered safe for appropriate candidates. Dr. Nawrocki provides ongoing monitoring through telehealth appointments to ensure your safety throughout treatment.

Both medications are administered via weekly subcutaneous injections, typically in the thigh, abdomen, or upper arm. The injections use pre-filled pens that are easy to use at home. Dr. Nawrocki provides comprehensive training on proper injection technique during your initial consultation, and ongoing support is available through our telehealth platform.